BillionToOne, Inc. vs CAREDX, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BLLN and CDNA diverge most: on net margin, BLLN reads 1.7% and CDNA reads -2.0%; on return on equity, BLLN reads 0.9% and CDNA reads -2.6%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BLLN | CDNA |
|---|---|---|
| Price | $130.22 | $39.73 |
| Market cap | $6.9B | $2.1B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/B | 13.66 | 6.73 |
| P/S | 23.87 | 5.11 |
| EV/EBITDA | 402.4 | — |
| Revenue growth | +100.6% | +19.7% |
| Gross margin | 73.0% | — |
| Operating margin | 16.4% | 1.0% |
| Net margin | 1.7% | -2.0% |
| Return on equity | 0.9% | -2.6% |
| Return on assets | 0.7% | -2.0% |
| Return on invested capital | 2.0% | -4.1% |
| FCF yield | 0.4% | 3.3% |
| Debt / equity | 0.18 | 0.00 |
| Current ratio | 10.92 | 3.40 |
| Altman Z (solvency) | 6.95 | 5.07 |
| Piotroski F (quality) | 5 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.